Activation of BKca channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Ma, Yu Guang ^a,b   Liu, Wen Chao ^a   Dong, Shuo ^c   Du, Cheng ^a   Wang, Xiao Jun ^d   Li, Jin Sheng ^d   Xie, Xiao Ping ^d   Wu, Li ^b   Ma, Da Chang ^b   Yu, Zhi Bin ^d   Xie, Man Jiang ^d  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; ESTROGEN RECEPTOR; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; TETRYLAMMONIUM; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNIT;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PATCH CLAMP; TREATMENT RESPONSE; WHOLE CELL; BREAST; BREAST TUMOR; DRUG EFFECT; DRUG POTENTIATION; FEMALE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNITS; MEMBRANE POTENTIAL, MITOCHONDRIAL;

EID: 84861376206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037451     Document Type: Article

References (37)

1. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, et al. (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178.
2. Guise TA, (2008) Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 34 (Suppl 1): S19-S24.
3. Neville-Webbe HL, Coleman RE, (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46: 1211-1222.
4. Bosch-Barrera J, Merajver SD, Menendez JA, Van PC, (2011) Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clin Transl Oncol 13: 148-155.
5. Green J, Lipton A, (2010) Anticancer properties of zoledronic acid. Cancer Invest 28: 944-957.
6. Senaratne SG, Colston KW, (2002) Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4: 18-23.
7. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, et al. (2011) Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 10: 2.
8. Sayers TJ, (2011) Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60: 1173-1180.
9. Hou S, Heinemann SH, Hoshi T, (2009) Modulation of BKCa channel gating by endogenous signaling molecules. Physiology (Bethesda) 24: 26-35.
10. Lee US, Cui J, (2010) BK channel activation: structural and functional insights. Trends Neurosci 33: 415-423.
11. Hill MA, Yang Y, Ella SR, Davis MJ, Braun AP, (2010) Large conductance, Ca2+-activated K+ channels (BKCa) and arteriolar myogenic signaling. FEBS Lett 584: 2033-2042.
12. Burg ED, Remillard CV, Yuan JX, (2008) Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br J Pharmacol 153 (Suppl 1): S99-S111.
13. Xie MJ, Ma YG, Gao F, Bai YG, Cheng JH, et al. (2010) Activation of BKCa channel is associated with increased apoptosis of cerebrovascular smooth muscle cells in simulated microgravity rats. Am J Physiol Cell Physiol 298: C1489-C1500.
14. Coiret G, Borowiec AS, Mariot P, Ouadid-Ahidouch H, Matifat F, (2007) The antiestrogen tamoxifen activates BK channels and stimulates proliferation of MCF-7 breast cancer cells. Mol Pharmacol 71: 843-851.
15. Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, et al. (2009) Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer 9: 258.
16. Brevet M, Ahidouch A, Sevestre H, Merviel P, El HY, et al. (2008) Expression of K+ channels in normal and cancerous human breast. Histol Histopathol 23: 965-972.
17. Cambien B, Rezzonico R, Vitale S, Rouzaire-Dubois B, Dubois JM, et al. (2008) Silencing of hSlo potassium channels in human osteosarcoma cells promotes tumorigenesis. Int J Cancer 123: 365-371.
18. Yan J, Aldrich RW, (2010) LRRC26 auxiliary protein allows BK channel activation at resting voltage without calcium. Nature 466: 513-516.
19. Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC, et al. (2007) KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene 26: 2525-2534.
20. Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, et al. (2010) Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Oncogene 29: 1553-1560.
21. Han X, Xi L, Wang H, Huang X, Ma X, et al. (2008) The potassium ion channel opener NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells. Biochem Biophys Res Commun 375: 205-209.
22. Abdullaev IF, Rudkouskaya A, Mongin AA, Kuo YH, (2010) Calcium-activated potassium channels BK and IK1 are functionally expressed in human gliomas but do not regulate cell proliferation. PLoS One 5: e12304.
23. Debska-Vielhaber G, Godlewski MM, Kicinska A, Skalska J, Kulawiak B, et al. (2009) Large-conductance K+ channel openers induce death of human glioma cells. J Physiol Pharmacol 60: 27-36.
24. Sontheimer H, (2008) An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood) 233: 779-791.
25. Weaver AK, Bomben VC, Sontheimer H, (2006) Expression and function of calcium-activated potassium channels in human glioma cells. Glia 54: 223-233.
26. Ouadid-Ahidouch H, Ahidouch A, (2008) K+ channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J Membr Biol 221: 1-6.
27. Roger S, Potier M, Vandier C, Le Guennec JY, Besson P, (2004) Description and role in proliferation of iberiotoxin-sensitive currents in different human mammary epithelial normal and cancerous cells. Biochim Biophys Acta 1667: 190-199.
28. Ma YG, Dong L, Ye XL, Deng CL, Cheng JH, et al. (2010) Activation of cloned BK(Ca) channels in nitric oxide-induced apoptosis of HEK293 cells. Apoptosis 15: 426-438.
29. Chang H, Ma YG, Wang YY, Song Z, Li Q, et al. (2011) High glucose alters apoptosis and proliferation in HEK293 cells by inhibition of cloned BK Ca channel. J Cell Physiol 226: 1660-1675.
30. Li J, Deng CL, Gao F, Cheng JH, Yu ZB, et al. (2009) Coexpression and characterization of the human large-conductance Ca(2+)-activated K (+) channel alpha + beta1 subunits in HEK293 cells. Mol Cell Biochem 331: 117-126.
31. Xue JH, Chen LH, Zhao HZ, Pu YD, Feng HZ, et al. (2011) Differential regulation and recovery of intracellular ca in cerebral and small mesenteric arterial smooth muscle cells of simulated microgravity rat. PLoS One 6: e19775.
32. Nelson MT, Quayle JM, (1995) Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268: C799-C822.
33. Xie MJ, Zhang LF, Ma J, Cheng HW, (2005) Functional alterations in cerebrovascular K(+) and Ca(2+) channels are comparable between simulated microgravity rat and SHR. Am J Physiol Heart Circ Physiol 289: H1265-H1276.
34. Tenta R, Pitulis N, Tiblalexi D, Consoulas C, Katopodis H, et al. (2008) Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Horm Metab Res 40: 737-745.
35. Mitrofan LM, Pelkonen J, Monkkonen J, (2009) The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone 45: 1153-1160.
36. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691.
37. Green JR, (2004) Bisphosphonates: preclinical review. Oncologist 9 (Suppl 4): 3-13.